
R^7 is hydrogen or halogen;

R^8 is methyl, methoxy, or fluoro; and

R^9 is hydrogen or fluoro.

[0012b] In another aspect of the present disclosure, there is provided a compound of Formula (II):



Formula (II)

or a pharmaceutically acceptable salt thereof, wherein



R^1 is methyl, ethyl, or fluoro(C1-2)alkyl;








R^2 is phenyl or phenyl substituted with 1 to 3 substituents independently selected from the group consisting of methyl, ethyl, methoxy, trifluoromethyl, and halogen;









R^3 is methyl, methoxy, or fluoro; and











R^4 is hydrogen or fluoro.


[0012c] In a further aspect of the present disclosure, there is provided a compound or a pharmaceutically acceptable salt thereof, wherein the compound is selected from the following table:

Compound No.	**Structure**
1	
2	

4	
5	
6	
7	
8	
9	
12	

13	
16	
17	
18	
19	
20	
21	
22	

33	
34	
36	
37	
38	
39	
40	
41	
42	
43	

44	

.


[0012d] In another aspect of the present disclosure, there is provided a pharmaceutical composition comprising a therapeutically effective amount of the compound disclosed herein, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or vehicle.

[0012e] In a further aspect of the present disclosure, there is provided a use of the compound disclosed herein or the pharmaceutical composition disclosed herein, in the manufacture of a medicament for the prevention or treatment of peripheral neuropathy, diabetes induced neuropathy, or fibrosis.

[0012f]In a further aspect of the present disclosure, there is provided a use of the compound disclosed herein or the pharmaceutical composition of disclosed herein, in the manufacture of a medicament for treating or ameliorating cytokine-induced inflammatory conditions in a subject in need thereof, wherein said cytokine comprises IL-1, TNF-α, IL-6, M-CSF, VCAM-1, or MCP-1.

[0012g] In another aspect of the present disclosure, there is provided a compound disclosed herein or the pharmaceutical composition disclosed herein, for use in therapy.

[00013] In an example, provided herein is a compound of Formula (**I**):




Formula (I)

or a pharmaceutically acceptable salt thereof, wherein R^1 is (C_{1-2})alkyl, or fluoro(C_{1-2})alkyl; R^2 is hydrogen, halogen, or (C_{1-3})alkyl; R^3 is hydrogen, or (C_{1-3})alkyl; R^4 is hydrogen, halogen, (C_{1-3})alkyl, or methoxy, R^5 is hydrogen, (C_{1-3})alkyl, halogen, or trifluoromethyl; R^6 is hydrogen, (C_{1-3})alkyl, halogen; R^7 is hydrogen or halogen; R^8 is hydrogen, methyl, methoxy, or fluoro; and R^9 is hydrogen or fluoro.

CLAIMS

What is claimed:

1. A compound of Formula (**I**):



Formula (I)

or a pharmaceutically acceptable salt thereof, wherein

R^1 is hydrogen, (C_{1-2})alkyl, or fluoro(C_{1-2})alkyl;

R^2 is hydrogen, halogen, or (C_{1-3})alkyl;

R^3 is hydrogen, or (C_{1-3})alkyl;

R^4 is hydrogen, halogen, (C_{1-3})alkyl, or methoxy, $N(C_{1-3})(C_{1-3})$;

R^5 is hydrogen, (C_{1-3})alkyl, halogen, or trifluoromethyl;

R^6 is hydrogen, (C_{1-3})alkyl, halogen;

R^7 is hydrogen or halogen;

R^8 is methyl, methoxy, or fluoro; and

R^9 is hydrogen or fluoro.

2. The compound of claim 1, wherein R^1 is methyl or ethyl.


3. The compound of claim 1, wherein R^2 is hydrogen, halogen, methyl, or isopropyl.

4. The compound of claim 1, wherein R^3 is hydrogen.

5. The compound of claim 1, wherein R^6 is methyl or isopropyl.

6. The compound of claim 1, wherein R^4 is dimethylamino.

7. The compound of claim 1, wherein the compound is of Formula (IA)




.

8. The compound of claim 7, wherein (i) R^2 and R^6 are each methyl; or (ii) R^2 and R^6 are each hydrogen.


9. The compound of claim 8, wherein (i) R^1 is ethyl; or (ii) R^8 is fluoro.

10. The compound of claim 1, wherein the compound is of Formula (IB)



, wherein R^8 is fluoro.

11. A compound of Formula (II):



Formula (II)

or a pharmaceutically acceptable salt thereof, wherein



R^1 is methyl, ethyl, or fluoro(C1-2)alkyl;











R^2 is phenyl or phenyl substituted with 1 to 3 substituents independently selected from the group consisting of methyl, ethyl, methoxy, trifluoromethyl, and halogen;












R^3 is methyl, methoxy, or fluoro; and












R^4 is hydrogen or fluoro.





12. A compound or a pharmaceutically acceptable salt thereof, wherein the compound is selected from the following table:

Compound No.	Structure
1	
2	

4	
5	
6	
7	
8	
9	
12	
13	
16	
17	

18	
19	
20	
21	
22	
23	
24	
25	
26	
27	
28	

29	
30	
31	
32	
33	
34	
36	
37	
38	
39	
40	

41	
42	
43	
44	

.

13. A pharmaceutical composition comprising a therapeutically effective amount of the compound of claim 1 to 12, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or vehicle.

14. Use of the compound of any one of claims 1 to 12 or the pharmaceutical composition of claim 13, in the manufacture of a medicament for the prevention or treatment of peripheral neuropathy, diabetes induced neuropathy, or fibrosis.

15. The use according to claim 14, wherein said peripheral neuropathy is chemotherapy-induced peripheral neuropathy, diabetic neuropathy, post-herpes zoster pain, or postherpetic neuralgia from shingles; said chemotherapy is platinum-based chemotherapy, alkaloid-based, or taxane-based chemotherapy; and/or said fibrosis is pulmonary fibrosis, hepatic fibrosis, or renal fibrosis.

16. The use according to claim 15, wherein said pulmonary fibrosis is associated with increased expression of IL-1, TNF-α, IL-6 or Collagens.

17. The use according to claim 15, wherein said pulmonary fibrosis is idiopathic pulmonary fibrosis or virus-induced fibrosis.

18. Use of the compound of any one of claims 1 to 12 or the pharmaceutical composition of claim 13, in the manufacture of a medicament for treating or ameliorating cytokine-induced

inflammatory conditions in a subject in need thereof, wherein said cytokine comprises IL-1, TNF-α, IL-6, M-CSF, VCAM-1, or MCP-1.

19. The use of claim 18, wherein said conditions are selected from a group consisting of coronavirus-induced pulmonary inflammation, acute respiratory distress syndrome, acute pulmonary inflammation, pulmonary fibrosis, liver fibrosis, and renal fibrosis.

20. The compound of any one of claims 1 to 12 or the pharmaceutical composition of claim 13, for use in therapy.